statistiche ricercatore

Continente	#
NA - Nord America	790
AS - Asia	370
EU - Europa	208
SA - Sud America	58
AF - Africa	17
OC - Oceania	4
Continente sconosciuto - Info sul continente non disponibili	1
Totale	1.448

Nazione	#
US - Stati Uniti d'America	784
SG - Singapore	124
IT - Italia	66
HK - Hong Kong	59
CN - Cina	46
BR - Brasile	42
DE - Germania	36
IN - India	36
VN - Vietnam	35
FI - Finlandia	23
FR - Francia	16
RU - Federazione Russa	11
SE - Svezia	11
BD - Bangladesh	10
BG - Bulgaria	10
JP - Giappone	10
PK - Pakistan	8
ZA - Sudafrica	8
EC - Ecuador	7
GB - Regno Unito	7
ID - Indonesia	7
IQ - Iraq	7
NL - Olanda	6
SA - Arabia Saudita	6
AR - Argentina	5
CA - Canada	5
AU - Australia	4
MA - Marocco	4
RO - Romania	4
UA - Ucraina	4
UZ - Uzbekistan	4
IE - Irlanda	3
TH - Thailandia	3
TR - Turchia	3
AT - Austria	2
BE - Belgio	2
IL - Israele	2
KE - Kenya	2
PL - Polonia	2
VE - Venezuela	2
AE - Emirati Arabi Uniti	1
AM - Armenia	1
BO - Bolivia	1
CI - Costa d'Avorio	1
CO - Colombia	1
DK - Danimarca	1
EG - Egitto	1
ES - Italia	1
HU - Ungheria	1
JM - Giamaica	1
JO - Giordania	1
KZ - Kazakistan	1
LK - Sri Lanka	1
LT - Lituania	1
MN - Mongolia	1
OM - Oman	1
PH - Filippine	1
PS - Palestinian Territory	1
PT - Portogallo	1
SY - Repubblica araba siriana	1
TN - Tunisia	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	1.448

Nome	#
Multiple sclerosis: changes in microarchitecture of white matter tracts after training with a video game balance board	193
The dual task-cost of standing balance affects quality of life in mildly disabled MS people	159
Effect on cognition of estroprogestins combined with Interferon Beta in multiple sclerosis: analysis of secondary outcomes from a randomised controlled trial	151
Lesion symptom map of cognitive–postural interference in multiple sclerosis	124
Predicting the profile of increasing disability in multiple sclerosis	114
A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta	100
The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence	90
Two determinants of late disability progression in multiple sclerosis: early inflammatory disease and old age in damaged brain.	85
Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis	75
High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline	66
null	64
Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis	60
null	58
null	58
null	55
null	51
Totale	1.503

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	3	0	0	0	0	0	0	0	0	0	0	3	0
2021/2022	127	4	4	12	3	18	5	1	9	10	8	32	21
2022/2023	79	22	10	1	4	17	8	2	1	5	2	7	0
2023/2024	42	2	8	0	4	1	13	0	1	0	5	1	7
2024/2025	275	0	12	11	9	19	15	13	13	51	22	15	95
2025/2026	548	61	32	45	42	88	25	58	37	69	58	33	0
Totale													1.503

Catalogo dei prodotti della ricerca